Celularity Inc. is a regenerative and cellular medicine company. It is developing and commercializing advanced biomaterial products and allogeneic, cryopreserved, placental-derived cell therapies, all derived from the postpartum placenta. Its therapeutic programs that target aging-related diseases, including degenerative diseases, cancer, and immune disorders, using mesenchymal-like adherent stromal cells, T-cells engineered with CAR (CAR T-cells), and genetically modified and unmodified natural killer (NK) cells. It develops, manufactures and commercializes advanced biomaterial products derived from structural tissue components of the postpartum placental tissues, including the umbilical cord. Its advanced biomaterials include Celularity Tendon Wrap, FUSE Bone Void Filler and Celularity Placental Matrix. Its advanced biomaterial products include Biovance, Interfyl and Rebound products. Its platform is Celularity IMPACT (Immuno-Modulatory Placental-derived Allogeneic Cell Therapy).
企業コードCELUW
会社名Celularity Inc
上場日May 23, 2019
最高経営責任者「CEO」Dr. Robert J. (Bob) Hariri, M.D., Ph.D.
従業員数- -
証券種類Company Warrant
決算期末- -
本社所在地170 Park Ave
都市FLORHAM PARK
証券取引所NASDAQ Capital Market Consolidated
国United States of America
郵便番号07932
電話番号19087682170
ウェブサイトhttps://celularity.com/
企業コードCELUW
上場日May 23, 2019
最高経営責任者「CEO」Dr. Robert J. (Bob) Hariri, M.D., Ph.D.
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし